Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Differentiated thyroid cancer Age: Adult |
Dose: 24 mg Frequency: once daily |
|
Indication: Renal cell carcinoma Age: Adult |
Dose: 18 mg Frequency: once daily Note: In combination with everolimus 5 mg once daily. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Differentiated Thyroid Carcinoma Condition: Severe renal impairment |
Dose: Tablet – 14 mg Frequency: once daily Note: Initial dose for differentiated thyroid carcinoma in patients with severe renal impairment |
|
Indication: Renal Cell Carcinoma Condition: Severe renal impairment |
Dose: Tablet – 10 mg Frequency: once daily Note: Initial dose for renal cell carcinoma in patients with severe renal impairment |
Administration
- Can be taken with or without food
- Take at same time each day
Side Effect
- Hypertension (73%)
- Diarrhea (67%)
- Fatigue (67%)
- Arthralgia/myalgia (62%)
- Decreased appetite (54%)
- Weight decreased (51%)
- Nausea (47%)
- Hypertension
- grades 3-4 (44%)
- Stomatitis (41%)
- Headache (38%)
- Vomiting (36%)
- Proteinuria (34%)
- Palmar-plantar erythrodysesthesia (32%)
- Abdominal pain (31%)
- Dysphonia (31%)
- Constipation (29%)
- Oral pain (25%)
- Cough (24%)
- Peripheral edema (21%)
- Rash (21%)
- Dysgeusia (18%)
- Dry mouth (17%)
- Dizziness (15%)
- Dyspepsia (13%)
- Alopecia (12%)
- Epistaxis (12%)
- Insomnia (12%)
- Urinary Tract Infection (UTI) (11%)
- Dental infection (10%)
- Hypotension (9%)
- Diarrhea, grades 3-4 (9%)
- Dehydration (9%)
- Prolonged QT interval (9%)
- Hypocalcemia (9%)
- Decreased appetite, grades 3-4 (7%)
- Hyperkeratosis (7%)
- Hypokalemia (6%)
- AST increased (5%)
- ALT increased (4%)
- Lipase increased (4%)
- Creatinine increased (3%)
- Nausea
- grades 3-4 (2%)
- Platelet count decreased (2%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4/Pgp substrates (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids)
|
Decreased exposure
|
|
Oral hormonal contraceptives
|
May reduce effectiveness
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 30°C in a dry place. Protect from light. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.